Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Alfonso García‐Valverde"'
Autor:
César Serrano, Ana Vivancos, Antonio López-Pousa, Judit Matito, Francesco M. Mancuso, Claudia Valverde, Sergi Quiroga, Stefania Landolfi, Sandra Castro, Cristina Dopazo, Ana Sebio, Anna C. Virgili, María M. Menso, Javier Martín-Broto, Miriam Sansó, Alfonso García-Valverde, Jordi Rosell, Jonathan A. Fletcher, Suzanne George, Joan Carles, Joaquín Arribas
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-12 (2020)
Abstract Background Gastrointestinal stromal tumor (GIST) initiation and evolution is commonly framed by KIT/PDGFRA oncogenic activation, and in later stages by the polyclonal expansion of resistant subpopulations harboring KIT secondary mutations af
Externí odkaz:
https://doaj.org/article/9f289e7391be4b1faf8ff1a0d9f5ce87
Autor:
Eva Serrano‐Candelas, Erola Ainsua‐Enrich, Arnau Navinés‐Ferrer, Paulo Rodrigues, Alfonso García‐Valverde, Sarah Bazzocco, Irati Macaya, Joaquín Arribas, César Serrano, Joan Sayós, Diego Arango, Margarita Martin
Publikováno v:
Molecular Oncology, Vol 12, Iss 8, Pp 1383-1397 (2018)
Gastrointestinal stromal tumors (GISTs) represent about 80% of the mesenchymal neoplasms of the gastrointestinal tract. Most GISTs contain oncogenic KIT (85%) or PDGFRA (5%) receptors. The kinase inhibitor imatinib mesylate is the preferential treatm
Externí odkaz:
https://doaj.org/article/44732c850c0545fbb2a5fcb190e1048f
Autor:
César Serrano, Oliver Politz, Joaquín Arribas, Jonathan A. Fletcher, Paolo Nuciforo, Joan Carles, Claudia Valverde, Garazi Serna, Jordi Rosell, Alfonso García-Valverde
KIT or PDGFRA gain-of-function mutations are the primary drivers of gastrointestinal stromal tumor (GIST) growth and progression throughout the disease course. The PI3K/mTOR pathway is critically involved in the transduction of KIT/PDGFRA oncogenic s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3915279d708e3bd12a8d2c0dc421c1be
https://doi.org/10.1158/1535-7163.c.6542790
https://doi.org/10.1158/1535-7163.c.6542790
Autor:
César Serrano, Oliver Politz, Joaquín Arribas, Jonathan A. Fletcher, Paolo Nuciforo, Joan Carles, Claudia Valverde, Garazi Serna, Jordi Rosell, Alfonso García-Valverde
Plasma levels of copanlisib of GIST-T1 and GIST-T1/670 xenografts at day 21. Plasma was collected 4 hours after last drug administration.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::057d484fc4044fbdd662405436c3a975
https://doi.org/10.1158/1535-7163.22520826
https://doi.org/10.1158/1535-7163.22520826
Autor:
César Serrano, Oliver Politz, Joaquín Arribas, Jonathan A. Fletcher, Paolo Nuciforo, Joan Carles, Claudia Valverde, Garazi Serna, Jordi Rosell, Alfonso García-Valverde
Drug combination effect of imatinib and copanlisib.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e3b6028edc346f09b6e077310054ead
https://doi.org/10.1158/1535-7163.22520808
https://doi.org/10.1158/1535-7163.22520808
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Elizabeth Proaño-Pérez, Eva Serrano-Candelas, Alfonso García-Valverde, Jordi Rosell, David Gómez-Peregrina, Arnau Navinés-Ferrer, Mario Guerrero, César Serrano, Margarita Martín
Publikováno v:
Cancer gene therapy.
Gastrointestinal stromal tumors (GISTs) are the most common neoplasms of mesenchymal origin, and most of them emerge due to the oncogenic activation of KIT or PDGFRA receptors. Despite their relevance in GIST oncogenesis, critical intermediates media
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c4e9a9148449eec12dc1f6fc77a913d
https://pubmed.ncbi.nlm.nih.gov/36400966
https://pubmed.ncbi.nlm.nih.gov/36400966
Autor:
Daniel L. Flynn, Jarnail Singh, Bryan D. Smith, César Serrano, Alfonso García-Valverde, Anu Gupta
Publikováno v:
Molecular Cancer Therapeutics. 20:1234-1245
The majority of gastrointestinal stromal tumors (GIST) harbor constitutively activating mutations in KIT tyrosine kinase. Imatinib, sunitinib, and regorafenib are available as first-, second-, and third-line targeted therapies, respectively, for meta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68cdc095c38062a9d744863d72f6bdfa
https://doi.org/10.1158/1535-7163.mct-20-0824
https://doi.org/10.1158/1535-7163.mct-20-0824
Publikováno v:
Expert Opinion on Emerging Drugs. 26:53-62
Oncogenic activation of KIT or PDGFRA receptor tyrosine kinases is the crucial event in gastrointestinal stromal tumor (GIST) biology. Seminal works during the past two decades have underscored, first, the continuous relevance of KIT/PDGFRA oncogenic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0245479a08858535289691565663be62
https://doi.org/10.1080/14728214.2021.1896704
https://doi.org/10.1080/14728214.2021.1896704
Publikováno v:
Diabetes práctica. 13
La diabetes mellitus y el cáncer son dos enfermedades que en ocasiones coexisten y cuya incidencia y prevalencia van en aumento. Ambas se consideran enfermedades multifactoriales y, por tanto, implican factores tanto genéticos como ambientales. En
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c15dbf709450f22a4b9ee42c2c0e081
https://doi.org/10.52102/diabet/pract/2022.2/art2
https://doi.org/10.52102/diabet/pract/2022.2/art2